<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="714">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05151861</url>
  </required_header>
  <id_info>
    <org_study_id>IMIB-RMV-2021-02</org_study_id>
    <nct_id>NCT05151861</nct_id>
  </id_info>
  <brief_title>Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy:</brief_title>
  <acronym>REMOVE</acronym>
  <official_title>Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy: Open and Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized trial is to investigate the effect of the complete removal of&#xD;
      pharmacological treatment in patients responding to cardiac resynchronization therapy with&#xD;
      recuperated LVEF in terms of imaging parameters (changes in LVEF and LV volume), as well as,&#xD;
      clinical parameters that translate into worsening of heart failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">May 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. A reduction in LVEF (Left ventricular ejection fraction) of more than 10%</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Number of patients with echocardiographic studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. An increase &gt;15% in the VTSVIi (The end-systolic volume of the indexed left ventricle) to the previous one and in a range higher than the normal value</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Number of patients with echocardiographic studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3. Clinical evidence of HF (Heart Failure) based on a global assessment, both clinical and analytical, together with the need to increase the dose of diuretics, as adjudicated by the research team.</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Number of patients with echocardiographic studies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total mortality, (Number )</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Total Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality,</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Total Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned hospital admission or emergency room visit for HF (Heart Failure)</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Total Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned hospital admission or emergency room visit for sustained atrial or ventricular arrhythmias (&gt;30 seconds).</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Total Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes with respect to baseline levels of BP (Blood pressure )</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes with respect to baseline levels of HR figures. (heart rate)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline LVEF</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline left ventricular end-diastolic volume (VTDVIi)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline body surface indexed left atrium volume (VAIi)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in global longitudinal strain (GLS).</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the quality of life questionnaires according to The Minnesota Living with Heart Failure (MLHFQ) scales.</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the quality of life questionnaires according to The Kansas City Cardiomyopathy Questionnaire (KCCQ) scales.</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Complete removal of pharmacological treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintenance of pharmacological treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Complete removal of pharmacological treatment</intervention_name>
    <description>Removal of treatment</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Maintenance of pharmacological treatment</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with a CRT device for at least one year due to the presence of LBBB and LVEF&#xD;
             &lt;40% of non-ischemic origin&#xD;
&#xD;
          2. Current LVEF ≥50% and normal volumes in two consecutive echocardiographic studies,&#xD;
             separated at least 3 months, and the last one performed in the previous 6 months.&#xD;
&#xD;
          3. Normally functioning CRT device with stimulation&gt; 95%.&#xD;
&#xD;
          4. NYHA functional class I-II.&#xD;
&#xD;
          5. Absence of admissions for HF in the last year.&#xD;
&#xD;
          6. NT-proBNP &lt;450pg/ml in sinus rhythm and &lt;900pg/ml in patients with atrial&#xD;
             fibrillation, in the previous 6 months.&#xD;
&#xD;
          7. Pharmacological treatment with beta-blockers, ACEIs/AIIRA/RNAI with or without MRA.&#xD;
&#xD;
          8. Older than 18 years.&#xD;
&#xD;
          9. Patients who have given their informed consent in writing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous episode of sustained ventricular tachycardia/recovered sudden&#xD;
             death/appropriate shock (in the case of a patient with an implantable&#xD;
             cardioverter-defibrillator associated with CRT).&#xD;
&#xD;
          2. Uncontrolled arterial hypertension (figures&gt; 140/90 mmHg).&#xD;
&#xD;
          3. Need to use beta-blockers at the medical discretion for other indications such as&#xD;
             heart rate (HR) control in atrial fibrillation (in the absence of ablation of the&#xD;
             atrioventricular node) or to control other supra or ventricular arrhythmias.&#xD;
&#xD;
          4. Severe valve disease.&#xD;
&#xD;
          5. Diabetic or hypertensive with microalbuminuria or proteinuria.&#xD;
&#xD;
          6. Renal failure with creatinine clearance &lt;30ml/min/1.73m2.&#xD;
&#xD;
          7. Fertile women who are neither using contraceptives nor surgically sterilized; pregnant&#xD;
             or lactating women.&#xD;
&#xD;
          8. You are currently participating in a clinical trial or have participated in the past&#xD;
             30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco José Pastor Pérez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HCUVA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco José Pastor Pérez, MD</last_name>
    <phone>968369500</phone>
    <email>franpastor79@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lola Serna Guirao</last_name>
    <email>lola.serna@carm.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

